论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
Authors Peng J, Yin JH, Cai SH, Yu T, Zhong CX
Published Date January 2015 Volume 2015:9 Pages 41—45
DOI http://dx.doi.org/10.2147/PPA.S71510
Received 21 July 2014, Accepted 29 September 2014, Published 7 January 2015
Abstract: Little is
known about the factors associated with patient compliance with nucleos(t)ide
analog (NUC) treatment for chronic hepatitis B (CHB). The purpose of this study
was to examine the association between sociodemographic and clinical
characteristics and adherence to NUCs among patients with CHB. A total of
211 CHB patients receiving NUC monotherapy were asked to report the number
of prescribed doses of medication they had taken during the last 90 days.
A total of four 3-month adherence scores were averaged to obtain a combined rate
of NUC adherence during a 1-year follow up period. The mean age of the patients
was 29.6 years, 79% were men, and 68% had no prior NUC treatment for CHB.
Females, patients without a previous NUC treatment, and those who had NUC drug
resistance showed better adherence to NUC treatment, and compliance was better
with telbivudine than with lamivudine and entecavir.
Keywords: chronic hepatitis B,
nucleos(t)ide analogues, adherence, follow-up, resistance